Pertussis Immunity and Response to Tetanus-Reduced Diphtheria-Reduced Pertussis Vaccine (Tdap) after Autologous Peripheral Blood Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 12, 2009, Pages 1538-1542

  Small, Trudy N ^a   Zelenetz, Andrew D ^a   Noy, Ariela ^a   Rice, R David ^a   Trippett, Tanya M ^a   Abrey, Lauren ^a   Portlock, Carol S ^a   McCullagh, Emily J ^a   Vanak, Jill M ^a   Mulligan, Ann Marie ^a   Moskowitz, Craig H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Pertussis; Transplantation; Vaccination

Indexed keywords

CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTERIAL IMMUNITY; CONTROLLED STUDY; DIPHTHERIA; DRUG RESPONSE; FEMALE; GRAFT RECIPIENT; HODGKIN DISEASE; HUMAN; IMMUNIZATION; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OLIGODENDROGLIOMA; PERTUSSIS; TETANUS; VACCINATION; VULNERABLE POPULATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; TETANUS; TRANSPLANTATION IMMUNOLOGY; WHOOPING COUGH; YOUNG ADULT;

EID: 70350763837     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.07.018     Document Type: Article

References (21)

1. Cherry J.D. Epidemiology of pertussis. Pediatr Infect Dis J 25 (2006) 361-362
2. Kretsinger K., Broder K.R., Cortese M.M., et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 15 RR-17 (2006) 1-37
3. Broder K.R., Cortese M.M., Iskander J.K., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 55 (2006) 1-34
4. Rothstein E., and Edwards K. Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J 24 (2005) S44-S47
5. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System and Supplemental Pertussis Surveillance System, 1996-2004 (2005), Centers for Disease Control and Prevention, Atlanta, GA
6. Food and Drug Administration. Product approval information-licensing action, package insert. Adacel™ (sanofi Pasteur) tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed. Available from: http://www.fda.gov/cber/lable/tdaave012306LB.pdf. Accessed June 1, 2009.
7. ® (GlaxoSmithKline Biologicals) tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed. Available from: http://www.fda.gov/cber/label/tdapgla122905LB.pdf. Accessed June 1, 2009.
8. Centers for Disease Control and Prevention. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep 58 (2009) 374-375
9. Small T.N., Rice R.D., McCullagh E., et al. Vaccine efficacy following autologous peripheral blood stem cell transplant for lymphoma. Blood 110 (2007) 603
10. McIntyre P.B., Burgess M.A., Eagan A., et al. Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: immunogenicity 5 years postvaccination. Vaccine 27 (2009) 1062-1066
11. Launay O., Toneatti C., Bernede C., et al. Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccines 5 (2009) 1-6
12. Edelman K., He Q., Makinen J., et al. Immunity to pertussis five years after booster immunization in adolescence. Clin Infect Dis 44 (2007) 1271-1277
13. Hoppe B.S., Moskowitz C.H., Filippa D.A., et al. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. J Clin Oncol 26 (2008) 1858-1864
14. Kewalramani T., Zelenetz A.D., Nimer S.D., et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103 (2004) 3684-3688
15. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97 (2001) 616-623
16. Center for International Blood and Marrow Transplant Research database. Accessed June 1, 2009.
17. Hammarstrom V., Pauksen K., Bjorkstrand B., et al. Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients. Bone Marrow Transplant 22 (1998) 67-81
18. Nordøy T., Husebekk A., and Aaberge I.S. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT: serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant 28 (2001) 681-687
19. Gandhi M.K., Egner W., Sizer L., et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant 28 (2001) 775-781
20. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb Mortal Wkly Rep 49 (2000) 1-128
21. Ljungman P., Engelhard D., de la Cámara R., et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 35 (2005) 737-746